Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

Today, more than 20 years since the first such biologic drugs were ... with biologics (for example, mAbs or recombinant proteins) that share similar action (now called biosimilar medicinal products).

Introduction of biosimilars for the rheumatology drug adalimumab ... could dissuade most prescribers from switching. Another example (and perhaps driver) of that latter success came in June ...

Janssen authorized Samsung to sell Pyzchiva, a Stelara biosimilar, in the U.S. starting ... Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies Stelara ...

Selarsdi is the second biosimilar to receive approval under a partnership between Iceland's Alvotech and Israel's Teva. Stelara is J&J’s best-selling drug, generating sales of around $10.9B in 2023.

Teva Pharmaceuticals and Alvotech last Friday launched Selarsdi, a biosimilar to Stelara. The Food and Drug Administration has allowed the use of Selarsdi as an "interchangeable" substitute only ...

Specialty drugs now account for 51% of total prescription spending, and this figure is expected to rise by 8% through 2025. Meanwhile, biosimilars present a potential $54 billion in savings over ...